Sanofi's Dupixent sales grow 45 percent in Q1

The sales for eczema drug Dupixent from Sanofi are growing steadily. During the year's first quarter, sales have increased by more than 45 percent.
Sanofi CEO Paul Hudson
Sanofi CEO Paul Hudson
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

Sales for Sanofi's major blockbuster drug Dupixent are mainly fueled by its use as a treatment for atopical dermatitis, but the drug's other approved indications are also gaining ground.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading